CannaPharmaRX (OTCMKTS:CPMD – Get Free Report) and Cytokinetics (NASDAQ:CYTK – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.
Profitability
This table compares CannaPharmaRX and Cytokinetics’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
CannaPharmaRX | N/A | N/A | -40.68% |
Cytokinetics | -14,141.74% | N/A | -67.32% |
Valuation & Earnings
This table compares CannaPharmaRX and Cytokinetics’ gross revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
CannaPharmaRX | N/A | N/A | $3.69 million | ($0.01) | -1.10 |
Cytokinetics | $7.53 million | 831.14 | -$526.24 million | ($5.40) | -11.05 |
Risk & Volatility
CannaPharmaRX has a beta of 2.36, suggesting that its share price is 136% more volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for CannaPharmaRX and Cytokinetics, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
CannaPharmaRX | 0 | 0 | 0 | 0 | N/A |
Cytokinetics | 0 | 3 | 15 | 0 | 2.83 |
Cytokinetics has a consensus price target of $77.06, indicating a potential upside of 29.10%. Given Cytokinetics’ higher probable upside, analysts clearly believe Cytokinetics is more favorable than CannaPharmaRX.
Summary
CannaPharmaRX beats Cytokinetics on 6 of the 9 factors compared between the two stocks.
About CannaPharmaRX
CannaPharmaRX, Inc. operates in the cannabis industry in Canada. It evaluates, negotiates, acquires, and develops various cannabis cultivation projects. The company was incorporated in 1998 and is based in Calgary, Canada.
About Cytokinetics
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
Receive News & Ratings for CannaPharmaRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CannaPharmaRX and related companies with MarketBeat.com's FREE daily email newsletter.